dbSNP Short Genetic Variations
Welcome to the Reference SNP (rs) Report
All alleles are reported in the Forward orientation. Click on the Variant Details tab for details on Genomic Placement, Gene, and Amino Acid changes. HGVS names are in the HGVS tab.
Reference SNP (rs) Report
This page reports data for a single dbSNP Reference SNP variation (RefSNP or rs) from the new redesigned dbSNP build.
Top of the page reports a concise summary for the rs, with more specific details included in the corresponding tabs below.
All alleles are reported in the Forward orientation. Use the Genomic View to inspect the nucleotides flanking the variant, and its neighbors.
For more information see Help documentation.
rs11554290
Current Build 157
Released September 3, 2024
- Organism
- Homo sapiens
- Position
-
chr1:114713908 (GRCh38.p14) Help
The anchor position for this RefSNP. Includes all nucleotides potentially affected by this change, thus it can differ from HGVS, which is right-shifted. See here for details.
- Alleles
- T>A / T>C / T>G
- Variation Type
- SNV Single Nucleotide Variation
- Frequency
-
C=0.000 (0/478, ALFA)C=0.000 (0/316, HapMap)
- Clinical Significance
- Reported in ClinVar
- Gene : Consequence
- NRAS : Missense Variant
- Publications
- 46 citations
- Genomic View
- See rs on genome
ALFA Allele Frequency
The ALFA project provide aggregate allele frequency from dbGaP. More information is available on the project page including descriptions, data access, and terms of use.
Population | Group | Sample Size | Ref Allele | Alt Allele | Ref HMOZ | Alt HMOZ | HTRZ | HWEP |
---|---|---|---|---|---|---|---|---|
Total | Global | 478 | T=1.000 | C=0.000 | 1.0 | 0.0 | 0.0 | N/A |
European | Sub | 0 | T=0 | C=0 | 0 | 0 | 0 | N/A |
African | Sub | 426 | T=1.000 | C=0.000 | 1.0 | 0.0 | 0.0 | N/A |
African Others | Sub | 0 | T=0 | C=0 | 0 | 0 | 0 | N/A |
African American | Sub | 426 | T=1.000 | C=0.000 | 1.0 | 0.0 | 0.0 | N/A |
Asian | Sub | 0 | T=0 | C=0 | 0 | 0 | 0 | N/A |
East Asian | Sub | 0 | T=0 | C=0 | 0 | 0 | 0 | N/A |
Other Asian | Sub | 0 | T=0 | C=0 | 0 | 0 | 0 | N/A |
Latin American 1 | Sub | 0 | T=0 | C=0 | 0 | 0 | 0 | N/A |
Latin American 2 | Sub | 0 | T=0 | C=0 | 0 | 0 | 0 | N/A |
South Asian | Sub | 0 | T=0 | C=0 | 0 | 0 | 0 | N/A |
Other | Sub | 52 | T=1.00 | C=0.00 | 1.0 | 0.0 | 0.0 | N/A |
Frequency tab displays a table of the reference and alternate allele frequencies reported by various studies and populations. Table lines, where Population="Global" refer to the entire study population, whereas lines, where Group="Sub", refer to a study-specific population subgroupings (i.e. AFR, CAU, etc.), if available. Frequency for the alternate allele (Alt Allele) is a ratio of samples observed-to-total, where the numerator (observed samples) is the number of chromosomes in the study with the minor allele present (found in "Sample size", where Group="Sub"), and the denominator (total samples) is the total number of all chromosomes in the study for the variant (found in "Sample size", where Group="Study-wide" and Population="Global").
DownloadStudy | Population | Group | Sample Size | Ref Allele | Alt Allele |
---|---|---|---|---|---|
Allele Frequency Aggregator | Total | Global | 478 | T=1.000 | C=0.000 |
Allele Frequency Aggregator | African | Sub | 426 | T=1.000 | C=0.000 |
Allele Frequency Aggregator | Other | Sub | 52 | T=1.00 | C=0.00 |
Allele Frequency Aggregator | European | Sub | 0 | T=0 | C=0 |
Allele Frequency Aggregator | Latin American 1 | Sub | 0 | T=0 | C=0 |
Allele Frequency Aggregator | Latin American 2 | Sub | 0 | T=0 | C=0 |
Allele Frequency Aggregator | South Asian | Sub | 0 | T=0 | C=0 |
Allele Frequency Aggregator | Asian | Sub | 0 | T=0 | C=0 |
HapMap | Global | Study-wide | 316 | T=1.000 | C=0.000 |
HapMap | African | Sub | 116 | T=1.000 | C=0.000 |
HapMap | American | Sub | 116 | T=1.000 | C=0.000 |
HapMap | Asian | Sub | 84 | T=1.00 | C=0.00 |
Variant Details tab shows known variant placements on genomic sequences: chromosomes (NC_), RefSeqGene, pseudogenes or genomic regions (NG_), and in a separate table: on transcripts (NM_) and protein sequences (NP_). The corresponding transcript and protein locations are listed in adjacent lines, along with molecular consequences from Sequence Ontology. When no protein placement is available, only the transcript is listed. Column "Codon[Amino acid]" shows the actual base change in the format of "Reference > Alternate" allele, including the nucleotide codon change in transcripts, and the amino acid change in proteins, respectively, allowing for known ribosomal slippage sites. To view nucleotides adjacent to the variant use the Genomic View at the bottom of the page - zoom into the sequence until the nucleotides around the variant become visible.
Sequence name | Change |
---|---|
GRCh38.p14 chr 1 | NC_000001.11:g.114713908T>A |
GRCh38.p14 chr 1 | NC_000001.11:g.114713908T>C |
GRCh38.p14 chr 1 | NC_000001.11:g.114713908T>G |
GRCh37.p13 chr 1 | NC_000001.10:g.115256529T>A |
GRCh37.p13 chr 1 | NC_000001.10:g.115256529T>C |
GRCh37.p13 chr 1 | NC_000001.10:g.115256529T>G |
NRAS RefSeqGene (LRG_92) | NG_007572.1:g.7987A>T |
NRAS RefSeqGene (LRG_92) | NG_007572.1:g.7987A>G |
NRAS RefSeqGene (LRG_92) | NG_007572.1:g.7987A>C |
Molecule type | Change | Amino acid[Codon] | SO Term |
---|---|---|---|
NRAS transcript | NM_002524.5:c.182A>T | Q [CAA] > L [CTA] | Coding Sequence Variant |
GTPase NRas | NP_002515.1:p.Gln61Leu | Q (Gln) > L (Leu) | Missense Variant |
NRAS transcript | NM_002524.5:c.182A>G | Q [CAA] > R [CGA] | Coding Sequence Variant |
GTPase NRas | NP_002515.1:p.Gln61Arg | Q (Gln) > R (Arg) | Missense Variant |
NRAS transcript | NM_002524.5:c.182A>C | Q [CAA] > P [CCA] | Coding Sequence Variant |
GTPase NRas | NP_002515.1:p.Gln61Pro | Q (Gln) > P (Pro) | Missense Variant |
Clinical Significance tab shows a list of clinical significance entries from ClinVar associated with the variation, per allele. Click on the RCV accession (i.e. RCV000001615.2) or Allele ID (i.e. 12274) to access full ClinVar report.
ClinVar Accession | Disease Names | Clinical Significance |
---|---|---|
RCV000418220.2 | Malignant neoplasm of body of uterus | Likely-Pathogenic |
RCV000418396.2 | Neoplasm of the large intestine | Likely-Pathogenic |
RCV000422640.2 | Glioblastoma | Likely-Pathogenic |
RCV000423898.2 | Hepatocellular carcinoma | Likely-Pathogenic |
RCV000424084.2 | Acute myeloid leukemia | Likely-Pathogenic |
RCV000426122.2 | Papillary renal cell carcinoma type 1 | Likely-Pathogenic |
RCV000428055.2 | Multiple myeloma | Likely-Pathogenic |
RCV000429082.2 | Ovarian serous cystadenocarcinoma | Likely-Pathogenic |
RCV000431333.2 | Thyroid tumor | Likely-Pathogenic |
RCV000433349.2 | Lung adenocarcinoma | Likely-Pathogenic |
RCV000433761.2 | B-cell chronic lymphocytic leukemia | Likely-Pathogenic |
RCV000435412.2 | Non-small cell lung carcinoma | Pathogenic |
RCV000435905.2 | Malignant melanoma of skin | Likely-Pathogenic |
RCV000436539.2 | Melanoma | Pathogenic |
RCV000438738.2 | Transitional cell carcinoma of the bladder | Likely-Pathogenic |
RCV000441171.2 | Neoplasm of brain | Likely-Pathogenic |
RCV000444188.2 | Adrenal cortex carcinoma | Likely-Pathogenic |
RCV000444754.2 | Nasopharyngeal neoplasm | Likely-Pathogenic |
RCV000444899.2 | Gastric adenocarcinoma | Likely-Pathogenic |
RCV002524687.3 | RASopathy | Uncertain-Significance |
ClinVar Accession | Disease Names | Clinical Significance |
---|---|---|
RCV000014914.11 | Thyroid cancer, nonmedullary, 2 | Pathogenic |
RCV000032847.11 | Epidermal nevus | Pathogenic |
RCV000037574.9 | Non-small cell lung carcinoma | Pathogenic |
RCV000114744.11 | Large congenital melanocytic nevus | Pathogenic |
RCV000114745.10 | Neurocutaneous melanocytosis | Pathogenic |
RCV000148032.7 | Linear nevus sebaceous syndrome | Pathogenic |
RCV000413804.7 | not provided | Pathogenic |
RCV000419710.4 | Papillary renal cell carcinoma type 1 | Likely-Pathogenic |
RCV000420832.4 | B-cell chronic lymphocytic leukemia | Likely-Pathogenic |
RCV000422078.4 | Adrenal cortex carcinoma | Likely-Pathogenic |
RCV000422278.4 | Ovarian serous cystadenocarcinoma | Likely-Pathogenic |
RCV000424455.4 | Neoplasm of brain | Likely-Pathogenic |
RCV000424721.4 | Lung adenocarcinoma | Likely-Pathogenic |
RCV000424960.4 | Melanoma | Pathogenic |
RCV000430407.4 | Malignant melanoma of skin | Likely-Pathogenic |
RCV000430593.4 | Nasopharyngeal neoplasm | Likely-Pathogenic |
RCV000431883.4 | Multiple myeloma | Likely-Pathogenic |
RCV000432961.4 | Hepatocellular carcinoma | Likely-Pathogenic |
RCV000435687.4 | Neoplasm of the large intestine | Pathogenic |
RCV000438052.4 | Glioblastoma | Likely-Pathogenic |
RCV000439264.4 | Gastric adenocarcinoma | Likely-Pathogenic |
RCV000440367.4 | Transitional cell carcinoma of the bladder | Likely-Pathogenic |
RCV000441317.4 | Acute myeloid leukemia | Likely-Pathogenic |
RCV000445249.4 | Malignant neoplasm of body of uterus | Likely-Pathogenic |
RCV003992155.1 | Noonan syndrome 6 | Uncertain-Significance |
ClinVar Accession | Disease Names | Clinical Significance |
---|---|---|
RCV000291285.2 | not provided | Pathogenic |
RCV000419053.2 | Adrenal cortex carcinoma | Likely-Pathogenic |
RCV000419201.2 | Multiple myeloma | Likely-Pathogenic |
RCV000420302.2 | B-cell chronic lymphocytic leukemia | Likely-Pathogenic |
RCV000421291.2 | Gastric adenocarcinoma | Likely-Pathogenic |
RCV000421496.2 | Malignant neoplasm of body of uterus | Likely-Pathogenic |
RCV000426654.2 | Nasopharyngeal neoplasm | Likely-Pathogenic |
RCV000427746.2 | Malignant melanoma of skin | Likely-Pathogenic |
RCV000428903.2 | Non-small cell lung carcinoma | Likely-Pathogenic |
RCV000430000.2 | Neoplasm of the large intestine | Likely-Pathogenic |
RCV000431592.2 | Melanoma | Pathogenic |
RCV000432170.2 | Glioblastoma | Likely-Pathogenic |
RCV000434604.2 | Neoplasm of brain | Likely-Pathogenic |
RCV000437312.2 | Transitional cell carcinoma of the bladder | Likely-Pathogenic |
RCV000437545.2 | Hepatocellular carcinoma | Likely-Pathogenic |
RCV000438468.2 | Thyroid tumor | Likely-Pathogenic |
RCV000439526.2 | Ovarian serous cystadenocarcinoma | Likely-Pathogenic |
RCV000439765.2 | Lung adenocarcinoma | Likely-Pathogenic |
RCV000444278.2 | Acute myeloid leukemia | Likely-Pathogenic |
RCV000444660.2 | Papillary renal cell carcinoma type 1 | Likely-Pathogenic |
RCV003155143.2 | Noonan syndrome 6 | Likely-Pathogenic |
Aliases tab displays HGVS names representing the variant placements and allele changes on genomic, transcript and protein sequences, per allele. HGVS name is an expression for reporting sequence accession and version, sequence type, position, and allele change. The column "Note" can have two values: "diff" means that there is a difference between the reference allele (variation interval) at the placement reported in HGVS name and the reference alleles reported in other HGVS names, and "rev" means that the sequence of this variation interval at the placement reported in HGVS name is in reverse orientation to the sequence(s) of this variation in other HGVS names not labeled as "rev".
Placement | T= | A | C | G |
---|---|---|---|---|
GRCh38.p14 chr 1 | NC_000001.11:g.114713908= | NC_000001.11:g.114713908T>A | NC_000001.11:g.114713908T>C | NC_000001.11:g.114713908T>G |
GRCh37.p13 chr 1 | NC_000001.10:g.115256529= | NC_000001.10:g.115256529T>A | NC_000001.10:g.115256529T>C | NC_000001.10:g.115256529T>G |
NRAS RefSeqGene (LRG_92) | NG_007572.1:g.7987= | NG_007572.1:g.7987A>T | NG_007572.1:g.7987A>G | NG_007572.1:g.7987A>C |
NRAS transcript | NM_002524.5:c.182= | NM_002524.5:c.182A>T | NM_002524.5:c.182A>G | NM_002524.5:c.182A>C |
NRAS transcript | NM_002524.4:c.182= | NM_002524.4:c.182A>T | NM_002524.4:c.182A>G | NM_002524.4:c.182A>C |
GTPase NRas | NP_002515.1:p.Gln61= | NP_002515.1:p.Gln61Leu | NP_002515.1:p.Gln61Arg | NP_002515.1:p.Gln61Pro |
Submissions tab displays variations originally submitted to dbSNP, now supporting this RefSNP cluster (rs). We display Submitter handle, Submission identifier, Date and Build number, when the submission appeared for the first time. Direct submissions to dbSNP have Submission ID in the form of an ss-prefixed number (ss#). Other supporting variations are listed in the table without ss#.
No | Submitter | Submission ID | Date (Build) |
---|---|---|---|
1 | CGAP-GAI | ss16257702 | Feb 28, 2004 (120) |
2 | OMICIA | ss169655349 | Aug 28, 2012 (137) |
3 | OMIM-CURATED-RECORDS | ss256302353 | Aug 26, 2010 (132) |
4 | DF-BWCC | ss275515086 | Nov 22, 2010 (133) |
5 | DF-BWCC | ss275515087 | Nov 22, 2010 (133) |
6 | DF-BWCC | ss275515088 | Nov 22, 2010 (133) |
7 | CLINVAR | ss2136847189 | Dec 04, 2016 (149) |
8 | ILLUMINA | ss3725056885 | Jul 12, 2019 (153) |
9 | CSS-BFX | ss8442107639 | Nov 02, 2024 (157) |
10 | CSS-BFX | ss8442107640 | Nov 02, 2024 (157) |
11 | CSS-BFX | ss8442107641 | Nov 02, 2024 (157) |
12 | EVA | ss8935520539 | Nov 02, 2024 (157) |
13 | EVA | ss8979259739 | Nov 02, 2024 (157) |
14 | EVA | ss8981439893 | Nov 02, 2024 (157) |
15 | LTPD | ss8981611167 | Nov 02, 2024 (157) |
16 | EVA | ss8981702327 | Nov 02, 2024 (157) |
17 | HapMap | NC_000001.11 - 114713908 | Apr 25, 2020 (154) |
18 | ALFA | NC_000001.11 - 114713908 | Nov 02, 2024 (157) |
19 | ClinVar | RCV000014914.11 | Nov 02, 2024 (157) |
20 | ClinVar | RCV000032847.11 | Nov 02, 2024 (157) |
21 | ClinVar | RCV000037574.9 | Nov 02, 2024 (157) |
22 | ClinVar | RCV000114744.11 | Nov 02, 2024 (157) |
23 | ClinVar | RCV000114745.10 | Nov 02, 2024 (157) |
24 | ClinVar | RCV000148032.7 | Nov 02, 2024 (157) |
25 | ClinVar | RCV000291285.2 | Nov 02, 2024 (157) |
26 | ClinVar | RCV000413804.7 | Nov 02, 2024 (157) |
27 | ClinVar | RCV000418220.2 | Nov 02, 2024 (157) |
28 | ClinVar | RCV000418396.2 | Nov 02, 2024 (157) |
29 | ClinVar | RCV000419053.2 | Nov 02, 2024 (157) |
30 | ClinVar | RCV000419201.2 | Nov 02, 2024 (157) |
31 | ClinVar | RCV000419710.4 | Nov 02, 2024 (157) |
32 | ClinVar | RCV000420302.2 | Nov 02, 2024 (157) |
33 | ClinVar | RCV000420832.4 | Nov 02, 2024 (157) |
34 | ClinVar | RCV000421291.2 | Nov 02, 2024 (157) |
35 | ClinVar | RCV000421496.2 | Nov 02, 2024 (157) |
36 | ClinVar | RCV000422078.4 | Nov 02, 2024 (157) |
37 | ClinVar | RCV000422278.4 | Nov 02, 2024 (157) |
38 | ClinVar | RCV000422640.2 | Nov 02, 2024 (157) |
39 | ClinVar | RCV000423898.2 | Nov 02, 2024 (157) |
40 | ClinVar | RCV000424084.2 | Nov 02, 2024 (157) |
41 | ClinVar | RCV000424455.4 | Nov 02, 2024 (157) |
42 | ClinVar | RCV000424721.4 | Nov 02, 2024 (157) |
43 | ClinVar | RCV000424960.4 | Nov 02, 2024 (157) |
44 | ClinVar | RCV000426122.2 | Nov 02, 2024 (157) |
45 | ClinVar | RCV000426654.2 | Nov 02, 2024 (157) |
46 | ClinVar | RCV000427746.2 | Nov 02, 2024 (157) |
47 | ClinVar | RCV000428055.2 | Nov 02, 2024 (157) |
48 | ClinVar | RCV000428903.2 | Nov 02, 2024 (157) |
49 | ClinVar | RCV000429082.2 | Nov 02, 2024 (157) |
50 | ClinVar | RCV000430000.2 | Nov 02, 2024 (157) |
51 | ClinVar | RCV000430407.4 | Nov 02, 2024 (157) |
52 | ClinVar | RCV000430593.4 | Nov 02, 2024 (157) |
53 | ClinVar | RCV000431333.2 | Nov 02, 2024 (157) |
54 | ClinVar | RCV000431592.2 | Nov 02, 2024 (157) |
55 | ClinVar | RCV000431883.4 | Nov 02, 2024 (157) |
56 | ClinVar | RCV000432170.2 | Nov 02, 2024 (157) |
57 | ClinVar | RCV000432961.4 | Nov 02, 2024 (157) |
58 | ClinVar | RCV000433349.2 | Nov 02, 2024 (157) |
59 | ClinVar | RCV000433761.2 | Nov 02, 2024 (157) |
60 | ClinVar | RCV000434604.2 | Nov 02, 2024 (157) |
61 | ClinVar | RCV000435412.2 | Nov 02, 2024 (157) |
62 | ClinVar | RCV000435687.4 | Nov 02, 2024 (157) |
63 | ClinVar | RCV000435905.2 | Nov 02, 2024 (157) |
64 | ClinVar | RCV000436539.2 | Nov 02, 2024 (157) |
65 | ClinVar | RCV000437312.2 | Nov 02, 2024 (157) |
66 | ClinVar | RCV000437545.2 | Nov 02, 2024 (157) |
67 | ClinVar | RCV000438052.4 | Nov 02, 2024 (157) |
68 | ClinVar | RCV000438468.2 | Nov 02, 2024 (157) |
69 | ClinVar | RCV000438738.2 | Nov 02, 2024 (157) |
70 | ClinVar | RCV000439264.4 | Nov 02, 2024 (157) |
71 | ClinVar | RCV000439526.2 | Nov 02, 2024 (157) |
72 | ClinVar | RCV000439765.2 | Nov 02, 2024 (157) |
73 | ClinVar | RCV000440367.4 | Nov 02, 2024 (157) |
74 | ClinVar | RCV000441171.2 | Nov 02, 2024 (157) |
75 | ClinVar | RCV000441317.4 | Nov 02, 2024 (157) |
76 | ClinVar | RCV000444188.2 | Nov 02, 2024 (157) |
77 | ClinVar | RCV000444278.2 | Nov 02, 2024 (157) |
78 | ClinVar | RCV000444660.2 | Nov 02, 2024 (157) |
79 | ClinVar | RCV000444754.2 | Nov 02, 2024 (157) |
80 | ClinVar | RCV000444899.2 | Nov 02, 2024 (157) |
81 | ClinVar | RCV000445249.4 | Nov 02, 2024 (157) |
82 | ClinVar | RCV002524687.3 | Nov 02, 2024 (157) |
83 | ClinVar | RCV003155143.2 | Nov 02, 2024 (157) |
84 | ClinVar | RCV003992155.1 | Nov 02, 2024 (157) |
History tab displays RefSNPs (Associated ID) from previous builds (Build) that now support the current RefSNP, and the dates, when the history was updated for each Associated ID (History Updated).
Submission IDs | Observation SPDI | Canonical SPDI | Source RSIDs |
---|---|---|---|
ss8442107639, ss8979259739, ss8981439893 | NC_000001.10:115256528:T:A | NC_000001.11:114713907:T:A | (self) |
RCV000418220.2, RCV000418396.2, RCV000422640.2, RCV000423898.2, RCV000424084.2, RCV000426122.2, RCV000428055.2, RCV000429082.2, RCV000431333.2, RCV000433349.2, RCV000433761.2, RCV000435412.2, RCV000435905.2, RCV000436539.2, RCV000438738.2, RCV000441171.2, RCV000444188.2, RCV000444754.2, RCV000444899.2, RCV002524687.3, ss275515086 | NC_000001.11:114713907:T:A | NC_000001.11:114713907:T:A | (self) |
ss8442107640, ss8935520539, ss8981611167, ss8981702327 | NC_000001.10:115256528:T:C | NC_000001.11:114713907:T:C | (self) |
RCV000014914.11, RCV000032847.11, RCV000037574.9, RCV000114744.11, RCV000114745.10, RCV000148032.7, RCV000413804.7, RCV000419710.4, RCV000420832.4, RCV000422078.4, RCV000422278.4, RCV000424455.4, RCV000424721.4, RCV000424960.4, RCV000430407.4, RCV000430593.4, RCV000431883.4, RCV000432961.4, RCV000435687.4, RCV000438052.4, RCV000439264.4, RCV000440367.4, RCV000441317.4, RCV000445249.4, RCV003992155.1, 159619, 7993568497, ss169655349, ss256302353, ss275515088, ss3725056885 | NC_000001.11:114713907:T:C | NC_000001.11:114713907:T:C | (self) |
ss16257702 | NT_032977.9:85228446:T:C | NC_000001.11:114713907:T:C | (self) |
ss8442107641, ss8935520539 | NC_000001.10:115256528:T:G | NC_000001.11:114713907:T:G | (self) |
RCV000291285.2, RCV000419053.2, RCV000419201.2, RCV000420302.2, RCV000421291.2, RCV000421496.2, RCV000426654.2, RCV000427746.2, RCV000428903.2, RCV000430000.2, RCV000431592.2, RCV000432170.2, RCV000434604.2, RCV000437312.2, RCV000437545.2, RCV000438468.2, RCV000439526.2, RCV000439765.2, RCV000444278.2, RCV000444660.2, RCV003155143.2, ss275515087, ss2136847189 | NC_000001.11:114713907:T:G | NC_000001.11:114713907:T:G | (self) |
Publications tab displays PubMed articles citing the variation as a listing of PMID, Title, Author, Year, Journal, ordered by Year, descending.
PMID | Title | Author | Year | Journal |
---|---|---|---|---|
1654209 | ras gene mutations in non-small cell lung cancers are associated with shortened survival irrespective of treatment intent. | Mitsudomi T et al. | 1991 | Cancer research |
2278970 | RAS gene mutations in childhood acute myeloid leukemia: a Pediatric Oncology Group study. | Vogelstein B et al. | 1990 | Genes, chromosomes & cancer |
2674680 | N-ras mutations in human cutaneous melanoma from sun-exposed body sites. | van 't Veer LJ et al. | 1989 | Molecular and cellular biology |
3122217 | RAS gene mutations in acute and chronic myelocytic leukemias, chronic myeloproliferative disorders, and myelodysplastic syndromes. | Janssen JW et al. | 1987 | Proceedings of the National Academy of Sciences of the United States of America |
6587382 | Mechanism of activation of an N-ras oncogene of SW-1271 human lung carcinoma cells. | Yuasa Y et al. | 1984 | Proceedings of the National Academy of Sciences of the United States of America |
8120410 | Ras mutations in human melanoma: a marker of malignant progression. | Ball NJ et al. | 1994 | The Journal of investigative dermatology |
12460918 | BRAF and RAS mutations in human lung cancer and melanoma. | Brose MS et al. | 2002 | Cancer research |
12727991 | RAS point mutations and PAX8-PPAR gamma rearrangement in thyroid tumors: evidence for distinct molecular pathways in thyroid follicular carcinoma. | Nikiforova MN et al. | 2003 | The Journal of clinical endocrinology and metabolism |
14508525 | BRAF mutations in papillary carcinomas of the thyroid. | Fukushima T et al. | 2003 | Oncogene |
16273091 | BRAF mutation predicts sensitivity to MEK inhibition. | Solit DB et al. | 2006 | Nature |
16291983 | Distinct sets of genetic alterations in melanoma. | Curtin JA et al. | 2005 | The New England journal of medicine |
16434492 | Implications of NRAS mutations in AML: a study of 2502 patients. | Bacher U et al. | 2006 | Blood |
17699718 | AZD6244 (ARRY-142886), a potent inhibitor of mitogen-activated protein kinase/extracellular signal-regulated kinase kinase 1/2 kinases: mechanism of action in vivo, pharmacokinetic/pharmacodynamic relationship, and potential for combination in preclinical models. | Davies BR et al. | 2007 | Molecular cancer therapeutics |
18390968 | Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers. | Adjei AA et al. | 2008 | Journal of clinical oncology |
18633438 | Genotypic and gene expression studies in congenital melanocytic nevi: insight into initial steps of melanotumorigenesis. | Dessars B et al. | 2009 | The Journal of investigative dermatology |
18948947 | Somatic mutations affect key pathways in lung adenocarcinoma. | Ding L et al. | 2008 | Nature |
19075190 | High-throughput sequencing screen reveals novel, transforming RAS mutations in myeloid leukemia patients. | Tyner JW et al. | 2009 | Blood |
19880792 | Cytostatic activity of adenosine triphosphate-competitive kinase inhibitors in BRAF mutant thyroid carcinoma cells. | Salerno P et al. | 2010 | The Journal of clinical endocrinology and metabolism |
20130576 | RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth. | Hatzivassiliou G et al. | 2010 | Nature |
20149136 | PLX4032, a selective BRAF(V600E) kinase inhibitor, activates the ERK pathway and enhances cell migration and proliferation of BRAF melanoma cells. | Halaban R et al. | 2010 | Pigment cell & melanoma research |
20179705 | RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF. | Poulikakos PI et al. | 2010 | Nature |
20406486 | Differential sensitivity of melanoma cell lines with BRAFV600E mutation to the specific Raf inhibitor PLX4032. | Søndergaard JN et al. | 2010 | Journal of translational medicine |
20619739 | Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis. | De Roock W et al. | 2010 | The Lancet. Oncology |
20736745 | NRAS mutations are rare in colorectal cancer. | Irahara N et al. | 2010 | Diagnostic molecular pathology |
21107323 | Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation. | Nazarian R et al. | 2010 | Nature |
21305640 | Frequency of KRAS, BRAF, and NRAS mutations in colorectal cancer. | Vaughn CP et al. | 2011 | Genes, chromosomes & cancer |
21576590 | NRAS-mutant melanoma: response to chemotherapy. | Soon CW et al. | 2011 | Archives of dermatology |
21729679 | Development of molecular biomarkers in individualized treatment of colorectal cancer. | De Mattos-Arruda L et al. | 2011 | Clinical colorectal cancer |
21829508 | PIK3CA mutations frequently coexist with RAS and BRAF mutations in patients with advanced cancers. | Janku F et al. | 2011 | PloS one |
22407852 | RAS mutations are frequent in FAB type M4 and M5 of acute myeloid leukemia, and related to late relapse: a study of the Japanese Childhood AML Cooperative Study Group. | Sano H et al. | 2012 | International journal of hematology |
22499344 | Keratinocytic epidermal nevi are associated with mosaic RAS mutations. | Hafner C et al. | 2012 | Journal of medical genetics |
22761467 | First-in-human, phase I dose-escalation study of the safety, pharmacokinetics, and pharmacodynamics of RO5126766, a first-in-class dual MEK/RAF inhibitor in patients with solid tumors. | Martinez-Garcia M et al. | 2012 | Clinical cancer research |
22773810 | Lung cancers with acquired resistance to EGFR inhibitors occasionally harbor BRAF gene mutations but lack mutations in KRAS, NRAS, or MEK1. | Ohashi K et al. | 2012 | Proceedings of the National Academy of Sciences of the United States of America |
23392294 | Multiple congenital melanocytic nevi and neurocutaneous melanosis are caused by postzygotic mutations in codon 61 of NRAS. | Kinsler VA et al. | 2013 | The Journal of investigative dermatology |
23414587 | MEK162 for patients with advanced melanoma harbouring NRAS or Val600 BRAF mutations: a non-randomised, open-label phase 2 study. | Ascierto PA et al. | 2013 | The Lancet. Oncology |
23515407 | Characteristics of lung cancers harboring NRAS mutations. | Ohashi K et al. | 2013 | Clinical cancer research |
23538902 | Inhibition of Wee1, AKT, and CDK4 underlies the efficacy of the HSP90 inhibitor XL888 in an in vivo model of NRAS-mutant melanoma. | Haarberg HE et al. | 2013 | Molecular cancer therapeutics |
23569304 | Pharmacodynamic effects and mechanisms of resistance to vemurafenib in patients with metastatic melanoma. | Trunzer K et al. | 2013 | Journal of clinical oncology |
23614898 | Discovery of a novel ERK inhibitor with activity in models of acquired resistance to BRAF and MEK inhibitors. | Morris EJ et al. | 2013 | Cancer discovery |
24006476 | Multilineage somatic activating mutations in HRAS and NRAS cause mosaic cutaneous and skeletal lesions, elevated FGF23 and hypophosphatemia. | Lim YH et al. | 2014 | Human molecular genetics |
24033266 | A systematic approach to assessing the clinical significance of genetic variants. | Duzkale H et al. | 2013 | Clinical genetics |
24370118 | Genetic mutation screen in early non--small-cell lung cancer (NSCLC) specimens. | Bar J et al. | 2014 | Clinical lung cancer |
25032700 | NCI-60 whole exome sequencing and pharmacological CellMiner analyses. | Reinhold WC et al. | 2014 | PloS one |
25157968 | Prospective enterprise-level molecular genotyping of a cohort of cancer patients. | MacConaill LE et al. | 2014 | The Journal of molecular diagnostics |
26619011 | Identifying recurrent mutations in cancer reveals widespread lineage diversity and mutational specificity. | Chang MT et al. | 2016 | Nature biotechnology |
29525983 | Identification of novel mutations in FFPE lung adenocarcinomas using DEPArray sorting technology and next-generation sequencing. | Lee JW et al. | 2018 | Journal of applied genetics |
The Flanks tab provides retrieving flanking sequences of a SNP on all molecules that have placements.
Genomic regions, transcripts, and products
Top▲
Help
NCBI Graphical Sequence Viewer display of the genomic region, transcripts and protein products for the reported RefSNP (rs).
Use the zoom option to view the nucleotides around the RefSNP and find other neighboring RefSNPs.
Visit Sequence Viewer for help with navigating inside the display and modifying the selection of displayed data tracks.
NCBI Graphical Sequence Viewer display of the genomic region, transcripts and protein products for the reported RefSNP (rs).
Use the zoom option to view the nucleotides around the RefSNP and find other neighboring RefSNPs.
Visit Sequence Viewer for help with navigating inside the display and modifying the selection of displayed data tracks.